About Us | Get a Quote | Contact Us
( only for international patients seeking treatment in India )
Email : info@wecareindia.com (preferred)

Patient Story
Successful Cancer surgery at We Care India partner hospital allows Henry Stolz to live a normal life despite a microendoscopic Decompression. We Care india helped Henry find best super specialised surgeon for his Condition.
Read : Robert's Story
See All : Success Stories










Nullam sodales, neque nec vehicula cursus, sapien sem.

Nonummy erat, eget sagittis metus odio non velit.





Combination Therapy
Combination therapy may benefit patients with specific genetic subtype of non-small cell lung cancer, study finds

Even when their tumors are shrinking in response to therapy, some non-small cell lung cancer (NSCLC) patients have a scattering of cancer cells that are undeterred by the drug, causing the tumor to resume its growth, Dana-Farber Cancer Institute and Massachusetts General Hospital (MGH) Cancer Center scientists report in the January issue of Cancer Cell.
The findings suggest that identifying such patients and treating them with a combination of drugs from the very start of therapy can produce longer remissions.

One of the triggers for resistance, the researchers found, is HGF, a ligand or "hook" that activates the MET protein.

Looking for a free cost estimate for cancer treatment abroad – click here

When activated, HGF works through two entirely different channels to produce drug resistance, the authors report. First, it can generate cell-growth signals through a protein called GAB1. Second, it expands the number of MET-amplified cancer cells, ensuring they will become the dominant type in the lung tumors.

"Not only can HGF spur cell growth on its own, it can speed up the process by which MET-amplified cells emerge and take over the composition of the tumor.

In about 20 percent of NSCLC patients who are resistant to Tarceva the mechanism is amplification of MET, and in another 20 percent it may involve HGF.

The findings suggest that patients whose NSCLC tumors harbor even a few MET-amplified cells prior to treatment would benefit from drugs that specifically target those cells, in combination with a tyrosine kinase inhibitor. Jänne notes that such drugs are already being studied in clinical trials.

Get an expert medical opinion – click here

A thorough analysis of a patient's cancer prior to treatment can establish how it would ultimately develop resistance to therapy, allowing us to tailor treatment with greater precision to prevent resistance.

"For example, cancers found to harbor a small population of cells with pre-existing MET amplification will likely benefit from adding MET inhibitors to initial treatment. Those without such cells may not benefit, and these patients can avoid the added toxicity of MET inhibitors and instead focus on other strategies to prevent their cancers from becoming resistant."

Do you have your medical reports, send us now for a free quote –
click here
For more information, medical assessment and medical quote
send your detailed medical history and medical reports
as email attachment to
Call: +91 9029304141 (10 am. To 8 pm. IST)
(Only for international patients seeking treatment in India)
Top
Worried for treatment, take a free second opinion – click here
Send Response

Gender :
  

For a detailed evaluation send patient’s medical reports / X rays / doctors notes to info@wecareindia.com







Medical Tourism Guide

Cancer Treatment Guide



 
We Care
 
  Paypal We accept Visa/Mater/ Amex

© 2010 We Care Health Services. All rights reserved.

This information is not designed to replace a physician's independent judgment about the appropriateness or risks of a procedure for a given patient.
Always consult your doctor about your medical condition. We Care Health Services does not provide medical advice, diagnosis or treatment. Use of the cancertreatment-wecareindia.com site is conditional upon your acceptance of our Terms and Conditions

cancertreatment-wecareindia is a member of wecareindia.com medical tourism information network
 

Combination Therapy India, Cancer Treatment Combination Therapy India, Combination Therapy Treatment Mumbai India, Combination Therapy Treatment Cost India, Combination Therapy Treatment Price India, Combination Therapy Treatment Clinic India, Endometrial Cancer, Esophageal Cancer, Extrahepatic Bile Duct Cancer, Combination Therapy Treatment Hospitals India, Combination Therapy Treatment Clinic Mumbai India, Combination Therapy Treatments Delhi Hospitals India, Combination Therapy Treatment Center India, Ewings Family of Tumors (PNET), Extracranial Germ Cell Tumor, Combination Therapy Treatment Mumbai India, Combination Therapy Treatment Health Services, Combination Therapy Treatment Abroad, Top Combination Therapy Treatment Doctors India, Combination Therapy Treatment Surgeons Delhi India, Gallbladder Cancer, Combination Therapy Treatment Symptoms India, Combination Therapy Treatment Cancer India, Combination Therapy Treatment Causes India, Gastric Cancer (Stomach), Combination Therapy Surgery Doctors India, Combination Therapy Surgery Hospitals Mumbai India, Germ Cell Tumor, Extragonadal, Gestational Trophoblastic Tumor